{
    "clinical_study": {
        "@rank": "28544", 
        "acronym": "HEXUGI", 
        "arm_group": [
            {
                "arm_group_label": "Treatment group, hexacapron , esomeprazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment group - receive I.V. esomeprazole 80 mg and  8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days."
            }, 
            {
                "arm_group_label": "Standard of care group, esomeprazole", 
                "arm_group_type": "Placebo Comparator", 
                "description": "* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to conduct a randomized control trial, double-blind study to\n      compare Hexacapron with standard of care treatment  to standard of care alone to evaluate\n      the efficacy of adding effect of Hexacapron to standard therapy by decreasing the episodes\n      of rebleeding and mortality in patient with upper gastrointestinal bleeding."
        }, 
        "brief_title": "The Use of Hexacapron in Upper Gastrointestinal Bleeding", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Upper Gastrointestinal Bleeding", 
            "Hexacapron", 
            "Hemostasis", 
            "Rebleeding", 
            "Mortality"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastrointestinal Hemorrhage", 
                "Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Research Objectives\n\n      To evaluate the efficacy of using hexacapron in treatment of upper gastrointestinal bleeding\n\n        -  Primary outcome:  Prevention of rebleeding manifested as hematemesis, melena and drop\n           in hemoglobin level by 2g% within 24 hours after therapeutic endoscopy\n\n        -  Secondary outcomes: rebleeding, need for surgery , 30 day mortality\n\n      Expected Significance- The sample size needed to detect a 10% absolute difference in the\n      proportion of rebleeding, drop in hemoglobin by 2g%  between the hexacapron treated group\n      and standard of care group groups with 80% power and 0.05 significant levels(alpha).\n\n      Research methods:\n\n        -  Prospective , randomized controlled trial , double blinded , single center\n\n        -  Duration : 2 years\n\n        -  ~ 300\u2264  participants ,18\u2264 years of age\n\n        -  Patients  18\u2264 years of age admitted to emergency department in Shaare Zedek Medical\n           Center with clinical signs and symptoms of upper gastrointestinal bleeding will receive\n           initial resuscitation and stabilization maintaining blood pressure and intravascular\n           volume.\n\n      Patients will be randomized to 3 groups:\n\n        1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with\n           concurrent hexacapron I.V. every 6 hours until 72 hours and then the patient continue\n           oral treatment 6 g /day for 7 days.\n\n        2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h\n           continuously\n\n             -  Every patient will undergo upper endoscopy within 12 hours of admission to\n                emergency department and receive treatment according to the endoscopic findings\n\n             -  If no reason for bleeding will be found in upper endoscopy , treatment will be\n                stopped and patient will be excluded\n\n             -  Every participant will fill a questionnaire with informed consent which will have\n                to be signed.\n\n                  -  If cannot sign due to his medical condition or disability his guardian will\n                     sign or first degree relative\n\n      Study population:\n\n      Patients  18\u2264 years of age admitted to emergency department in Shaare Zedek MedicalCenter\n      with clinical signs and symptoms of upper gastrointestinal bleeding including hematemesis,\n      melena and drop in hemoglobin level by 2g%\n\n      Included:\n\n        -  Patients  18\u2264 years of age admitted to emergency department in Shaare Zedek Medical\n           Center with clinical signs,  symptoms and laboratory of upper gastrointestinal bleeding\n\n        -  Hospitalized patients  in Shaare Zedek Medical Center with clinical signs,  symptoms\n           and laboratory of upper gastrointestinal bleeding \u2022 Patients , guardian or family\n           member who can sign on informed consent\n\n      Excluded:\n\n        -  Pregnancy, lactation\n\n        -  History of thromboembolic event\n\n        -  Allergic reaction to the drug\n\n        -  Lower gastrointestinal bleeding\n\n        -  Patient receive anticoagulation treatment\n\n        -  Receive drug with interaction to hexacapron"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients  18\u2264 years of age admitted to emergency department in Shaare Zedek\n             MedicalCenter with clinical signs,  symptoms and laboratory of upper gastrointestinal\n             bleeding\n\n          -  Hospitalized patients  in Shaare Zedek Medical Center with clinical signs, symptoms\n             and laboratory of upper gastrointestinal bleeding\n\n          -  Patients , guardian or family member who can sign on informed consent\n\n        Exclusion Criteria:\n\n        Pregnancy, lactation\n\n          -  History of thromboembolic event\n\n          -  Allergic reaction to the drug\n\n          -  Lower gastrointestinal bleeding\n\n          -  Patient receive anticoagulation treatment\n\n          -  Receive drug with interaction to hexacapron"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071316", 
            "org_study_id": "Hexacap - 1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment group, hexacapron , esomeprazole", 
                "description": "1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid)  I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.", 
                "intervention_name": "Hexacapron( Tranexamic acid)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard of care group, esomeprazole", 
                "description": "2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously", 
                "intervention_name": "esomeprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tranexamic Acid", 
                "Omeprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "upper gastrointestinal bleeding", 
            "Hexacapron", 
            "hemostasis"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "melamudb@szmc.org.il", 
                "last_name": "Bernardo Melamud, Dr.", 
                "phone": "00972-2-6666116"
            }, 
            "contact_backup": {
                "email": "dwen@szmc.org.il", 
                "last_name": "Dov Wengrover, Dr.", 
                "phone": "00972-2-6666067"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "3235"
                }, 
                "name": "Shaare Zedek Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Alon Scwartz, Dr.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Newman, Dr.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Use of Hexacapron in Upper Gastrointestinal Bleeding", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israeli Health Ministry':'", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All patients will undergo upper endoscopy within 12 hours from admission to assess their cause of upper GI bleeding .Patients will be evaluated according to the intervention group or standard of care group if there is another episode of bleeding or not during the first 48 hours after the first bleeding episode or within 24 hours after the first endoscopy was done", 
            "measure": "Prevention of rebleeding manifested as hematemesis, melena and                    drop in hemoglobin level by 2g% within 24 hours after therapeutic endoscopy", 
            "safety_issue": "No", 
            "time_frame": "Will be assessed 48 hours after admission to hospital"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071316"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaare Zedek Medical Center", 
            "investigator_full_name": "Dr Bernardo Melamud", 
            "investigator_title": "Dr.Bernardo Melamud", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "All patients will be assessed for more bleeding episodes (>2 episodes) , need fo surgery or mortality during the 30 days after the first bleeding episode", 
            "measure": "Rebleeding, need for surgery , 30 day mortality", 
            "safety_issue": "No", 
            "time_frame": "will be assessed after 30 days from admission to hospital"
        }, 
        "source": "Shaare Zedek Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shaare Zedek Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}